Blood cancer charity Leukaemia & Lymphoma Research welcomes the government’s announcement to extend the Cancer Drugs Fund until 2016, but points out that more needs to be done to improve access to treatments.
Research Director Professor Chris Bunce says:
“This is excellent news and it will reassure those blood cancer patients who are already receiving medicines through the Cancer Drugs Fund. However, it is a temporary measure as it doesn’t resolve the bigger question of how we get new treatments to patients faster, and how we make new treatments more accessible.
“The Cancer Drugs Fund is only available to people living in England yet Leukaemia & Lymphoma Research invests in research and clinical trials across the whole of the UK. As a result it is frustrating that these life-improving drugs are not available to all UK patients.”
The Cancer Drugs Fund enables patients to access medicines that would not otherwise be available on the NHS.